First In Human Study of CX-801 in Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.